DEFA14A: Alzamend Neuro Sets 2026 Annual Meeting Agenda

Alzamend Neuro, Inc. announced its upcoming annual stockholders' meeting on April 17, 2026, to vote on director elections, auditor ratification, executive compensation, a new stock incentive plan, equity issuances, and a potential reverse stock split.

Summary

• Alzamend Neuro, Inc. will hold its Annual Meeting of Stockholders virtually on April 17, 2026, at 12:00 p.m. ET.
• Stockholders will vote on the election of seven directors: William B. Horne, Milton C. Ault, III, Stephan Jackman, Henry C.W. Nisser, Mark Gustafson, Lynne F. McGrath, and Jeffrey Oram.
• A proposal to ratify Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2026, will be voted upon.
• Stockholders will cast a non-binding advisory vote on the compensation of named executive officers.
• Approval of the Company's 2025 Stock Incentive Plan is on the agenda.
• A proposal to approve equity issuances to directors and executive officers, in compliance with Nasdaq Listing Rule 5635(c), will be presented.
• Stockholders will vote on an amendment to the Company's Certificate of Incorporation to effect a reverse stock split of common stock by a ratio of not less than one-for-two and not more than one-for-ten, at any time prior to April 16, 2027, with the exact ratio determined by the Board.
• A proposal to approve one or more adjournments of the Annual Meeting to permit further solicitation of proxies, if necessary, will also be voted on.
• The Board of Directors recommends a vote FOR all the nominees listed and FOR Proposals 2-7.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a largely procedural filing for an annual meeting, but the proposal for a reverse stock split introduces a notable element that can be perceived negatively by the market, indicating potential challenges with share price.

Positives

• The company is conducting its annual meeting, a standard corporate governance practice.
• The Board's recommendation to ratify Haskell & White LLP as the independent auditor ensures continuity in financial oversight.

Negatives

• The proposal for a reverse stock split (ratio of 1-for-2 to 1-for-10) often signals a need to increase share price, potentially to meet exchange listing requirements, which can be perceived negatively by the market.

Risks

• A reverse stock split, if approved and implemented, may not achieve its intended purpose of increasing the stock price or improving market perception, and could potentially lead to further stock price decline.
• The reverse stock split could reduce the liquidity of the common stock due to a lower number of outstanding shares.
• The approval of the 2025 Stock Incentive Plan and equity issuances to directors and executive officers could lead to dilution for existing shareholders.

Future Outlook

The company is seeking approval for a reverse stock split, which aims to increase the per-share trading price of its common stock, potentially to maintain compliance with exchange listing requirements or enhance its appeal to a broader investor base. The approval of a new stock incentive plan indicates a forward-looking strategy for employee and executive compensation.

Management Comments

• The Board of Directors recommends a vote FOR all the nominees listed for election.
• The Board of Directors recommends a vote FOR Proposals 2-7, which include auditor ratification, executive compensation, the 2025 Stock Incentive Plan, equity issuances, the reverse stock split, and meeting adjournments.

Industry Context

StockSavvy.ai notes that reverse stock splits are often employed by companies seeking to meet minimum bid price requirements for stock exchange listings or to enhance stock appeal to institutional investors, though they do not change underlying company value. The approval of a new stock incentive plan and equity issuances are common practices for public companies to attract and retain talent and align management interests with shareholders.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Will vote on significant corporate actions, including director elections, executive compensation, potential dilution from new stock plans and equity issuances, and the impact of a reverse stock split on share count and price.
• Employees and Executives: Will be impacted by the approval of the 2025 Stock Incentive Plan and equity issuances, which are designed to incentivize and retain key personnel.

Next Steps

• Stockholders are encouraged to view proxy materials and vote online or request a paper copy.
• The Annual Meeting of Stockholders will be held virtually on April 17, 2026, to vote on the proposals.
• If the reverse stock split is approved, the Board of Directors will determine the exact ratio within the approved range prior to April 16, 2027.

Key Dates

Keywords

Alzamend Neuro, ALZN, Proxy Statement, Annual Meeting, Reverse Stock Split, Corporate Governance, Stock Incentive Plan, Director Election, SEC Filing, Executive Compensation